ArticlePloS one2009
Leptin administration favors muscle mass accretion by decreasing FoxO3a and increasing PGC-1alpha in ob/ob mice.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 1 synthesis or guideline pooled it, 134 citations in OpenAlex.
- Irisin, a link among fatty liver disease, physical inactivity and insulin resistance.International journal of molecular sciences · 2014Pooled it
- Energy deprivation alters in a leptin- and cortisol-independent manner circulating levels of activin A and follistatin but not myostatin in healthy males.The Journal of clinical endocrinology and metabolism · 2011Trial
- Leptin treatment reduces body fat but does not affect lean body mass or the myostatin-follistatin-activin axis in lean hypoleptinemic women.American journal of physiology. Endocrinology and metabolism · 2011Trial
- Tissue-Specific Multi-Omics Integration Demonstrates Molecular Signatures Connecting Obesity to Immune Vulnerability.Metabolites · 2026Article
- Chronic inflammation as a driving factor for sarcopenia: an update on pathophysiology and future therapeutic targets.Frontiers in pharmacology · 2026Review
- Leptin's potential mechanisms in ICU-acquired weakness.Lipids in health and disease · 2025Review
- Exercise-Induced Muscle-Fat Crosstalk: Molecular Mediators and Their Pharmacological Modulation for the Maintenance of Metabolic Flexibility in Aging.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Plasma biomarkers for monitoring muscle function and physical performance decline in older adults: A 2-year longitudinal study.The journal of nutrition, health & aging · 2025Article
- Body composition analysis in adolescents idiopathic scoliosis and its correlation with the severity of scoliosis.Scientific reports · 2025Article
- Review
- Overexpression of PRDM16 improves muscle function after rotator cuff tears.Journal of shoulder and elbow surgery · 2024Article
- Control of muscle satellite cell function by specific exercise-induced cytokines and their applications in muscle maintenance.Journal of cachexia, sarcopenia and muscle · 2024Review
- Incident low muscle mass is associated with greater lung disease and lower circulating leptin in a tobacco-exposed longitudinal cohort.Respiratory research · 2023Article
- Probing microstructural changes in muscles of leptin-deficient zebrafish by non-invasive ex-vivo magnetic resonance microimaging.PloS one · 2023Article
- The crosstalk between BAT thermogenesis and skeletal muscle dysfunction.Frontiers in physiology · 2023Review
- Comparative transcriptome analysis of longissimus dorsi tissues with different intramuscular fat contents from Guangling donkeys.BMC genomics · 2022Article
- Leptin mediates the regulation of muscle mass and strength by adipose tissue.The Journal of physiology · 2022Article
- Role of insulin resistance and the gut microbiome on urine oxalate excretion in ob/ob mice.Physiological reports · 2022Article
- Obesity attenuates inflammation, protein catabolism, dyslipidaemia, and muscle weakness during sepsis, independent of leptin.Journal of cachexia, sarcopenia and muscle · 2022Article
- Modified UCN2 peptide treatment improves skeletal muscle mass and function in mouse models of obesity-induced insulin resistance.Journal of cachexia, sarcopenia and muscle · 2021Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Absence of leptin has been associated with reduced skeletal muscle mass in leptin-deficient ob/ob mice. The aim of our study was to examine the effect of leptin on the catabolic and anabolic pathways regulating muscle mass. Gastrocnemius, extensor digitorum longus and soleus muscle mass as well as fiber size were significantly lower in ob/ob mice compared to wild type littermates, being significantly increased by leptin administration (P<0.001). This effect was associated with an inactivation of the muscle atrophy-related transcription factor forkhead box class O3 (FoxO3a) (P<0.05), and with a decrease in the protein expression levels of the E3 ubiquitin-ligases muscle atrophy F-box (MAFbx) (P<0.05) and muscle RING finger 1 (MuRF1) (P<0.05). Moreover, leptin increased (P<0.01) protein expression levels of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha), a regulator of muscle fiber type, and decreased (P<0.05) myostatin protein, a negative regulator of muscle growth. Leptin administration also activated (P<0.01) the regulators of cell cycle progression proliferating cell nuclear antigen (PCNA) and cyclin D1, and increased (P<0.01) myofibrillar protein troponin T. The present study provides evidence that leptin treatment may increase muscle mass of ob/ob mice by inhibiting myofibrillar protein degradation as well as enhancing muscle cell proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.